Halozyme Preliminary 2024 Estimated Ranges Consistent With Guidance; Raises FY25 Guidance

(RTTNews) - Halozyme Therapeutics (HALO) reiterated full year 2024 financial guidance and increased full year 2025 and multi-year financial guidance. For 2025, the company now expects: non-GAAP EPS in a range of $4.95 to $5.35, revised from prior guidance range of $4.45 to $4.85. Total revenue is now expected in a range of $1.15 billion to $1.225 billion, revised from prior guidance range of $1.095 billion to $1.17 billion.

Preliminary estimates of results for the twelve months ended December 31, 2024, include: Non-GAAP EPS in a range of $4.00 to $4.20; and total revenue in a range of $970 million to $1.02 billion.

The company also announced it has recently entered into a new $250 million accelerated share repurchase program under previously announced $750 million share repurchase program.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.